organon news - Search News

Roivant, Organon

Barron's on MSN · 6d

Roivant Flips a Skin Drug to Organon

Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, and then selling them for big returns.

GlobalData on MSN · 5d

Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis.

Organon to buy Roivant's dermatology unit for up to $1.2 billion

However, Organon was down 1.4%. Dermavant's Vtama cream, approved by the U.S. Food and Drug Administration in May 2022, treats psoriasis, a common long-term inflammatory skin disease. The FDA is also reviewing an application to expand the use of the drug ...

Business Insider · 6d

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an

2d

Organon: A Surprising Deal

Organon shares have stabilized in recent times, with gradual debt reduction and structural growth allowing for a valuation re ...

Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama

With its latest acquisition, women’s health outfit Organon is bringing its dermatology business to the U.S. with a ...

Organon makes dermatology play with $1.2bn Dermavant buyout

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...

6d

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...

Organon to acquire Dermavant in $1.2B deal

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

Bernie Sanders keeps the heat on Novo’s high prices

Sen. Bernie Sanders has been probing the high prices that Novo charges for Ozempic and Wegovy. Yesterday, he share that ...

Organon Issues 2023 ESG Report, Highlighting Strides in Women’s Health Equity and Environmental Stewardship

Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today released its 2023 Environmental, ...

5d

Assessing Organon’s Strategic Acquisition of Dermavant: A Balanced Hold Recommendation Amid Growth and Challenges

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), retaining the price target of ...

5d

Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results